Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has earned a consensus rating of "Hold" from the nine research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $9.29.

A number of analysts have recently commented on the company. William Blair cut Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Monday, March 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, May 13th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $4.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Stifel Nicolaus cut Neumora Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the company from $6.00 to $2.00 in a research note on Friday, March 7th. Finally, Bank of America reissued an "underperform" rating and issued a $1.00 target price (down from $7.00) on shares of Neumora Therapeutics in a research note on Wednesday, April 2nd.

Neumora Therapeutics Trading Down 1.3%

Shares of NASDAQ:NMRA traded down $0.01 during midday trading on Friday, hitting $0.71. The company had a trading volume of 438,155 shares, compared to its average volume of 1,517,516. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $17.19. The firm has a fifty day simple moving average of $0.74 and a 200 day simple moving average of $3.50. The stock has a market cap of $114.73 million, a price-to-earnings ratio of -0.38 and a beta of 2.96.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02). Equities analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Institutional investors have recently modified their holdings of the company. Swiss National Bank bought a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $1,168,000. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Neumora Therapeutics by 273.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company's stock valued at $5,523,000 after purchasing an additional 381,676 shares in the last quarter. Capital International Investors lifted its holdings in shares of Neumora Therapeutics by 692.1% in the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company's stock valued at $39,224,000 after purchasing an additional 3,233,179 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $281,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Neumora Therapeutics by 23.0% in the fourth quarter. Wells Fargo & Company MN now owns 70,653 shares of the company's stock valued at $749,000 after purchasing an additional 13,196 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.